山东大学学报 (医学版) ›› 2018, Vol. 56 ›› Issue (5): 1-7.doi: 10.6040/j.issn.1671-7554.0.2018.228
• 妇科恶性肿瘤及罕见肿瘤保留生育功能的临床研究专题 •
杨佳欣,沈铿,王遥
YANG Jiaxin, SHEN Keng, WANG Yao
摘要： 妇科恶性肿瘤的传统治疗手段为手术、化疗与放疗,这些治疗对生殖器官的功能有破坏性,肿瘤治疗后患者丧失生育与生理功能。如何在恶性肿瘤治疗的同时保留患者的生育功能一直是妇科肿瘤医生追求的目标;肿瘤早期诊断、治愈率的提高、辅助生育技术的发展均为保留生育功能的治疗提供了条件,同时也提出了挑战。
中图分类号:
| [1] Angarita AM, Johnson CA, Fader AN, et al. Fertility preservation: a key survivorship issue for young women with cancer[J]. Front Oncol, 2016, 6: 102. doi: 10.3389/fonc.2016.00102. [2] Aviki EM, Abu-Rustum NR. A call to standardize our approach to fertility-sparing surgery in patients with gynecologic cancers[J]. Gynecol Oncol, 2017, 147(3): 491-492. [3] Shah JS, Guerra R, Bodurka DC, et al. Factors influencing fertility-sparing treatment for gynecologic malignancies: a survey of Society of Gynecologic Oncology members[J]. Gynecol Oncol, 2017, 147(3): 497-502. [4] Vitale SG, La Rosa VL, Rapisarda AMC, et al. The importance of fertility preservation counseling in patients with gynecologic cancer[J]. J Reprod Infertil, 2017, 18(2): 261-263. [5] Siegel RL, Miller KD, Jemal A. Cancer statistics[J]. CA Cancer J Clin, 2015, 65(1): 5-29. [6] 沈铿,崔恒,丰有吉.常见妇科恶性肿瘤诊治指南[M]. 北京: 人民卫生出版社, 2014: 147. [7] Dargent D. Radical abdominal trachelectomy and pelvic lymphadenectomy with uterine conservation and subsequent pregnancy in the treatment of early invasive cervical cancer[J]. Am J Obstet Gynecol, 2002, 187(6): 1728. [8] Sato S, Itamochi H, Sugiyama T. Fertility-sparing surgery for uterine cervical cancer[J]. Future Oncol, 2016, 12(20): 2345-2355. [9] Tomao F, Maruccio M, Preti EP, et al. Conization in early stage cervical cancer: pattern of recurrence in a 10-year single-institution experience[J]. Int J Gynecol Cancer, 2017, 27(5): 1001-1008. [10] Willows K, Lennox G, Covens A. Fertility-sparing management in cervical cancer: balancing oncologic outcomes with reproductive success[J]. Gynecol Oncol Res Pract, 2016, 3: 9. [11] Koh WJ, Greer BE, Abu-Rustum NR, et al. Cervical Cancer, Version 2.2015[J]. J Natl Compr Canc Netw, 2015, 13(4): 395-404. [12] Bentivegna E, Gouy S, Maulard A, et al. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review[J]. Lancet Oncol, 2016, 17(6): e240-e253. [13] Wright JD, Nathavith Arana R, Lewin SN, et al. Fertility-conserving surgery for young women with stage IA1 cervical cancer: safety and access[J]. Obstet Gynecol, 2010, 115(3): 585-590. [14] Xu L, Sun FQ, Wang ZH. Radical trachelectomy versus radical hysterectomy for the treatment of early cervical cancer: a systematic review[J]. Acta Obstet. Gynecol, Scand, 2011, 90(11): 1200-1209. [15] Lanowska M, Mangler M, Spek A, et al. Radical vaginal trachelectomy(RVT)combined with laparoscopic lymphadenectomy: prospective study of 225 patients with early-stage cervical cancer[J]. Int J Gynecol Cancer, 2011, 21(8): 1458-1464. [16] Estevez JP, Hequet D, Dubot C, et al. Fertility sparing treatment in women affected by cervical cancer larger than 2 cm[J]. Bull Cancer, 2016, 103(2): 173-179. [17] Wang D, Yang J, Shen K, et al. Neoadjuvant chemotherapy followed by fertility-sparing surgery for women with stage IB1 cervical cancer[J]. J Gynecol Oncol, 2013, 24(3): 287-290. [18] Bentivegna E, Maulard A, Pautier P, et al. Fertility results and pregnancy outcomes after conservative treatment of cervical cancer: a systematic review of the literature[J]. Fertil Steril, 2016, 106(5): 1195-1211. [19] Kyrgiou M, Mitra A, Paraskevaidis E. Fertility and early pregnancy outcomes following conservative treatment for cervical intraepithelial neoplasia and early cervical cancer[J]. JAMA Oncol, 2016, 2(11): 1496-1498. [20] Okugawa K, Kobayashi H, Sonoda K, et al. Oncologic and obstetric outcomes and complications during pregnancy after fertility-sparing abdominal trachelectomy for cervical cancer: a retrospective review[J]. Int J Gynecol Cancer, 2017, 22(2): 340-346. [21] 曹冬焱, 杨佳欣, 向阳, 等. 早期子宫颈癌患者行阴式子宫颈广泛性切除术的治疗效果及生育结局[J]. 中华妇产科杂志, 2014, 49(4): 249-253. CAO Dongyan, YANG Jiaxin, XIANG Yang, et al. Oncologic and fertility outcomes of young patients with early stage of cervical cancer treated by vaginal radical trachelectomy[J]. Chinese Journal of Obstetrics and Gynecology, 2014, 49(4): 249-253. [22] Cao DY, Yang JX, Wu XH, et al. Comparisons of vaginal and abdominal radical trachelectomy for early-stage cervical cancer: preliminary results of a multi-center research in China[J]. Br J Cancer, 2014, 110(2): 341-352. [23] Solheim O, Gershenson DM, Trope CG, et al. Prognostic factors in malignant ovarian germ cell tumours(The Surveillance, Epidemiology and End Results experience 1978-2010)[J]. Eur J Cancer, 2014, 50(11): 1942-1950. [24] Gouy S, Saidani M, Maulard A, et al. Is uterine preservation combined with bilateral salpingo-oophorectomy to promote subsequent fertility safe in infiltrative mucinous ovarian cancer?[J]. Gynecol Oncol Rep, 2017, 22: 52-54. doi:10.1016/j.gore.2017.09.011. [25] Nayyar N, Lakhwani P, Goel A, et al. Management of borderline ovarian tumors-still a gray zone[J]. Indian J Surg Oncol, 2017, 8(4): 607-614. [26] Park JY. Safety of fertility-sparing surgery for stage I ovarian clear cell carcinoma[J]. J Gynecol Oncol, 2017, 28(6): e91. doi: 10.3802/jgo.2017.28.e91. [27] Morgan RJJr, Armstrong DK, Alvarez RD, et al. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2016, 14(9): 1134-1163. [28] Zapadiel I, Diestro MD, Aletti G. Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes[J]. Eur J Surg Oncol, 2014, 40(4):387-393. [29] Nasioudis D, Chapman-Davis E, Frey MK, et al. Could fertility-sparing surgery be considered for women with early stage ovarian clear cell carcinoma?[J]. J Gynecol Oncol, 2017, 28(6): e71. doi: 10.3802/jgo.2017.28.e71. [30] Kajiyama H, Shibata K, Mizuno M, et al. Fertility-sparing surgery in patients with clear-cell carcinoma of the ovary: is it possible?[J]. Hum Reprod, 2011, 26(12): 3297-3302. [31] Kajiyama H, Mizuno M, Shibata K, et al. Recurrence-predicting prognostic factors for patients with early-stage epithelial ovarian cancer undergoing fertility-sparing surgery: a multi-institutional study[J]. Eur J Obstet Gynecol Reprod Biol, 2014, 175: 97-102. doi: 10.1016/j.ejogrb.2014.01.014. [32] Ditto A, Marinelli F, Bogani G, et al. Long-term safety of fertility sparing surgery in early stage ovarian cancer: comparison to standard radical surgical procedures[J]. Gynecol oncol, 2015, 138(1): 78-82. [33] Fruscio R, Ceppi L, Corso S, et al. Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer[J]. Br J Cancer, 2016, 115(6): 641-648. [34] Ghezzi F, Cromi A, Fanfani F, et al. Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: a multi-institutional experience[J]. Gynecol Oncol, 2016, 141(3): 461-465. [35] Jiang X, Yang J, Yu M, et al. Oncofertility in patients with stage I epithelial ovarian cancer: fertility-sparing surgery in young women of reproductive age[J]. World J Surg Oncol, 2017, 15(1): 154. doi: 10.1186/s12957-017-1222-4. [36] Chen M, Jin Y, Li Y, et al. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer[J]. Int J Gynaecol Obstet, 2016, 132(1): 34-38. [37] Kim SR, van der Zanden C, Ikiz H, et al. Fertility-sparing management using progestin for young women with endometrial cancer from a population-based study[J]. J Obstet Gynaecol Can, 2018, 40(3): 328-333. [38] Pronin SM, Novikova OV, Andreeva JY, et al. Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential[J]. Int J Gynecol Cancer, 2015, 25(6): 1010-1014. [39] Tamauchi S, Kajiyama H, Utsumi F, et al. Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer[J]. J Obstet Gynaecol Res, 2018, 44(1): 151-156. [40] Zhou H, Cao D, Yang J, et al. Gonadotropin-releasing hormone agonist combined with a levonorgestrel-releasing intrauterine system or letrozole for fertility-preserving treatment of endometrial carcinoma and complex atypical hyperplasia in young women[J]. Int J Gynecol Cancer, 2017, 27(6): 1178-1182. [41] Zhou R, Yang Y, Lu Q, et al. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients[J]. Gynecol Oncol, 2015, 139(3): 424-428. [42] 曹冬焱, 俞梅, 杨佳欣, 等. 大剂量孕激素治疗早期子宫内膜癌及子宫内膜重度不典型增生患者的妊娠结局及相关因素分析[J]. 中华妇产科杂志, 2013, 48(7): 519-522. CAO Dongyan, YU Mei, YANG Jiaxin, et al. Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin[J]. Chinese Journal of Obstetrics and Gynecology, 2013, 48(7): 519-522. [43] 俞梅, 曹冬焱, 杨佳欣, 等. 早期子宫内膜癌孕激素保留生育功能治疗的多中心临床研究[C].中华医学会第十次全国妇产科学术会议, 2012. [44] 左东华, 杨佳欣. 子宫内膜癌保守治疗失败的相关问题分析[J]. 中国医师杂志, 2015, 17(8): 1140-1143. ZUO Donghua, YANG Jiaxin. Analysis of failure-related issues of young patients with endometrial carcinoma who undergo the conservative treatment[J]. Journal of Chinese Physician, 2015, 17(8): 1140-1143. [45] Qin Y, Yu Z, Yang J, et al. Oral progestin treatment for early-stage endometrioal cancer[J]. Int J Gynecol Cancer, 2016, 26(6): 1081-1091. [46] Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine Neoplasms, Version 1. 2018, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2018, 16(2): 170-199. [47] Turkmen O, Karalok A, Basaran D, et al. Fertility-sparing surgery should be the standard treatment in patients with malignant ovarian germ cell Tumors[J]. J Adolesc Young Adult Oncol, 2017, 6(2): 270-276. [48] Powell JL, Kotwall CA, Shiro BC. Fertility-sparing surgery for advanced juvenile granulosa cell tumor of the ovary[J]. J Pediatr Adolesc Gynecol, 2014, 274: e89-e92. [49] Nasioudis D, Frey MK, Chapman-Davis E, et al. Fertility-preserving surgery for advanced stage ovarian germ cell tumors[J]. Gynecol Oncol, 2017, 147(3): 493-496. [50] 刘倩, 丁西来, 杨佳欣, 等. 卵巢恶性生殖细胞肿瘤手术治疗方式及疗效的多中心临床研究[J]. 中华妇产科杂志, 2013, 48(3): 188-192. LIU Qian, DING Xilai, YANG Jiaxin, et al. Multicenter randomized controlled clinical study for the operative treatment of malignant ovarian germ cell tumor[J]. Chinese Journal of Obstetrics and Gynecology, 2013, 48(3): 188-192. [51] Israel F, Sheri L, Lalit P, et al. Vaginal tumors on childhood: the experience of St. Jude Childrens Research Hospital[J]. J Pediatr Surg, 2011, 46(11): 2071-2075. [52] Tao T, Yang J, Cao D, et al. Conservative treatment and long-term follow up of endodermal sinus tumor of the vagina[J]. Gynecol Oncol, 2012, 125(2): 358-361. [53] Yang J, Yang J, Yu M, et al. Clinical study on female genital tract rhabdomyosarcoma in childhood: changes during 20 years in one center[J]. Int J Gynecol Cancer, 2017, 27(2): 311-314. [54] Magers MJ, Kao CS, Cole CD, et al. “Somatic-type” malignancies arising from testicular germ cell tumors: a clinicopathologic study of 124 cases with emphasis on glandular tumors supporting frequent yolk sac tumor origin[J]. Am J Surg Pathol, 2014, 38(10): 1396-1409. [55] Lim D, Oliva E. Ovarian sex cord-stromal tumours: an update in recent molecular advances[J]. Pathology, 2018, 50(2): 178-189. [56] Schultz KAP, Williams GM, Kamihara J, et al. DICER1 and associated conditions: identification of at-risk individuals and recommended surveillance strategies[J]. Clin Cancer Res, 2018, 17. pii: clincanres.3089.2017.doi:10.1158/1078-0432.CCR-17-3089.[Epub ahead of print] [57] Swanson CL, Kumar A, Maharaj JM, et al. Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis[J]. Gynecol Oncol, 2018, 3. pii: S0090-8258(18)30072-6.doi: 10.1016/j.ygyno.2018.01.033.[Epub ahead of print] [58] Takeda T, Tsuji K, Banno K, et al. Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer[J]. J Gynecol Oncol, 2018, 30. doi: 10.3802/jgo.2018.29.e29.[Epub ahead of print] [59] Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma[J]. Nature, 2013, 497(7447): 67-73. [60] Lavoue V, Rousselin A, Delplanque S, et al. Can new molecular profiles in epithelial ovarian cancer modify therapeutics?[J]. J Gynecol Obstet Hum Reprod, 2017, 46(2): 107-112. [61] Cheng X, Zhang L, Chen Y, et al. Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancer[J]. J Ovarian Res, 2017, 10(1): 75. doi: 10.1186/s13048-017-0369-5. [62] Cicchillitti L, Corrado G, De Angeli M, et al. Circulating cell-free DNA content as blood based biomarker in endometrial cancer[J]. Oncotarget, 2017, 8(70): 115230-115243. [63] Kuhlmann JD, Wimberger P, Bankfalvi A, et al. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance[J]. Clin Chem, 2014, 60(10): 1282-1289. [64] Traver S, Assou S, Scalici E, et al. Cell-free nucleic acids as non-invasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy[J]. Hum Reprod Update, 2014, 20(6): 905-923. [65] Bertoldo MJ, Walters KA, Ledger WL, et al. In-vitro regulation of primordial follicle activation: challenges for fertility preservation strategies[J]. Reprod Biomed Online, 2018, 13. pii: S1472-6483(18)30051-8. doi: 10.1016/j.rbmo.2018.01.014.[Epub ahead of print] [66] Chan JL, Wang ET. Oncofertility for women with gynecologic malignancies[J]. Gynecol Oncol, 2017, 144(3): 631-636. |
| [1] | 鹿群,赵璐璐. 子宫内膜癌、子宫内膜非典型增生保留生育功能后助孕策略[J]. 山东大学学报 (医学版), 2022, 60(9): 35-41. |
| [2] | 赵舸,邹存华,宋冬冬,赵淑萍. 丹参酮IIA对子宫内膜癌细胞增殖与凋亡的影响[J]. 山东大学学报 (医学版), 2022, 60(9): 53-58. |
| [3] | 刘腾,马迎春. 基于生物信息库病例分析ECT2在子宫内膜癌中的表达及临床意义[J]. 山东大学学报 (医学版), 2022, 60(8): 63-71. |
| [4] | 张艺馨,赵玉立,封丽. 超声特征及术前CA-125联合对51例卵巢交界性及Ⅰ期恶性肿瘤的鉴别诊断[J]. 山东大学学报 (医学版), 2022, 60(7): 104-109. |
| [5] | 申晓畅,孙一卿,颜磊,赵兴波. 芳基烃受体核转位因子样蛋白2在子宫内膜癌中的表达[J]. 山东大学学报 (医学版), 2022, 60(5): 74-80. |
| [6] | 陈泉材,韩赛,刘露,孙雨,尤学武,张俊华,张友忠. CDC7、MCM4在105例宫颈病变组织中的表达及意义[J]. 山东大学学报 (医学版), 2022, 60(1): 34-39. |
| [7] | 哈春芳,李茹月. 卵巢癌耐药机制与靶向治疗策略的研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 117-123. |
| [8] | 王璐,赵新蕊,朱琳. 25例早期宫颈癌无瘤化免举宫腹腔镜子宫切除术临床效果[J]. 山东大学学报 (医学版), 2021, 59(6): 76-80. |
| [9] | 陈君宇, 曹冬焱. 以脑梗为首发的卵巢癌病例报告[J]. 山东大学学报 (医学版), 2021, 59(5): 110-112. |
| [10] | 丁菲,姜洁. 姜黄素对子宫内膜癌孕激素抵抗的影响[J]. 山东大学学报 (医学版), 2021, 59(4): 35-41. |
| [11] | 梁婷婷,杨勇霞,侯丛哲,黄太胜,王华丽,朱琳. PAX1基因甲基化与宫颈高级别上皮内病变及高危型HPV分型的关联性[J]. 山东大学学报 (医学版), 2021, 59(11): 48-52. |
| [12] | 王正阳,夏艳,师凯旋,陶琨,王小杰. 曲美替尼在卵巢癌中对PAX8的表达作用[J]. 山东大学学报 (医学版), 2021, 59(10): 23-29. |
| [13] | 王宝金,赵欣欣,李霞,马倩,王新月,孙阳,史中娜. miR-203靶向Survivin抑制卵巢癌细胞增殖、迁移与侵袭[J]. 山东大学学报 (医学版), 2020, 58(12): 23-28. |
| [14] | 丁长宽,陈健行. 蛋白酶体抑制剂硼替佐米联合顺铂对宫颈癌细胞增殖的影响[J]. 山东大学学报 (医学版), 2018, 56(1): 70-75. |
| [15] | 刘京康,杨建勇,孟丽华,姜洁. 血清miR-17-92簇在HPV阳性宫颈癌中的早期诊断价值[J]. 山东大学学报（医学版）, 2017, 55(5): 86-90. |
|
||
